Literature DB >> 16189119

In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.

Lucio Vera-Cabrera1, Jorge Castro-Garza, Adrian Rendon, Jorge Ocampo-Candiani, Oliverio Welsh, Sung Hak Choi, Kym Blackwood, Carmen Molina-Torres.   

Abstract

The in vitro activities of DA-7867, a novel oxazolidinone, and garenoxacin (BMS-284756) were compared to those of linezolid in 67 susceptible and drug-resistant clinical isolates of Mycobacterium tuberculosis. DA-7867 was the most active drug with an MIC(90) of 0.125 microg/ml, compared to the MIC(90)s of 4 microg/ml of garenoxacin and 2 microg/ml of linezolid.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16189119      PMCID： PMC1251498          DOI： 10.1128/AAC.49.10.4351-4353.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

2.  Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model.

Authors:  M H Cynamon; S P Klemens; C A Sharpe; S Chase
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.

Authors:  Dongeun Yong; Jong Hwa Yum; Kyungwon Lee; Yunsop Chong; Sung Hak Choi; Jae Keol Rhee
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

Review 4.  The TB epidemic from 1992 to 2002.

Authors:  Mario C Raviglione
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

5.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

6.  Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.

Authors:  S G Franzblau; R S Witzig; J C McLaughlin; P Torres; G Madico; A Hernandez; M T Degnan; M B Cook; V K Quenzer; R M Ferguson; R H Gilman
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

7.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  The global situation of MDR-TB.

Authors:  Marcos A Espinal
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

9.  In vitro activities of new antimicrobials against Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Sung H Choi; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Authors:  Alexandra Aubry; Xiao-Su Pan; L Mark Fisher; Vincent Jarlier; Emmanuelle Cambau
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
  10 in total
  8 in total

1.  In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Eva Gonzalez; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Victor M Velazquez-Moreno; Sung Hak Choi; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Current development and future prospects in chemotherapy of tuberculosis.

Authors:  Eric L Nuermberger; Melvin K Spigelman; Wing Wai Yew
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

3.  Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis.

Authors:  Devyani Deshpande; Shashikant Srivastava; Eric Nuermberger; Thearith Koeuth; Katherine R Martin; Kayle N Cirrincione; Pooi S Lee; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

4.  The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.

Authors:  Shashikant Srivastava; Devyani Deshpande; Eric Nuermberger; Pooi S Lee; Kayle Cirrincione; Keertan Dheda; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

5.  Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.

Authors:  K N Williams; C K Stover; T Zhu; R Tasneen; S Tyagi; J H Grosset; E Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 6.  Prodrugs for the treatment of neglected diseases.

Authors:  Man Chin Chung; Elizabeth Igne Ferreira; Jean Leandro Santos; Jeanine Giarolla; Daniela Gonçales Rando; Adélia Emília Almeida; Priscila Longhin Bosquesi; Renato Farina Menegon; Lorena Blau
Journal:  Molecules       Date:  2007-03-19       Impact factor: 4.411

Review 7.  Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors:  Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

8.  Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis.

Authors:  Lucio Vera-Cabrera; Alejandra Daw-Garza; Salvador Said-Fernández; Hector Gerardo Lozano-Garza; Noemi Waksman de Torres; Norma Cavazos Rocha; Jorge Ocampo-Candiani; Sung-Hak Choi; Oliverio Welsh
Journal:  PLoS Negl Trop Dis       Date:  2008-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.